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Abstract
It is increasingly evident that the pathobiologic alterations in asthma are 
heterogeneous and that analysis of the airway transcriptome can define patterns 
of gene expression that reveal transcriptional endotypes of asthma (TEA clusters) 
that are clinically meaningful. To determine if this is possible, we conducted a 
novel unsupervised Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway 
based clustering analysis of gene expression in the induced sputum of adults and 
children with asthma. The identified TEA clusters were correlated to 
demographical, physiological and inflammatory phenotype of the disease. 
Differentially expressed genes between each TEA cluster and controls were 
identified and analyzed for functional enrichment analysis to better understand the 
pathobiology of each TEA cluster. 
Conclusion
Non-invasive analysis of the sputum transcriptome conducted in this 
study identified three TEA clusters with different clinical and physiologic 
characteristics of disease. Two TEA clusters are associated with 
phenotypes of severe diseases: a history of a near fatal asthma, a 
history of hospitalization for asthma, and weakly overlap with SARP 
clusters and TH2 high/low defined disease. This suggests that the TEA 
clusters are unique and driven by biologic phenomena that are 
“upstream” or parallel to Th2 inflammation.
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Results
Three TEA clusters were identified. TEA cluster 1 had the most subjects with a 
history of intubation (P=0.05), a lower pre-bronchodilator FEV1 (P=0.006), a higher 
bronchodilator response (P=0.03), and higher exhaled nitric oxide levels (P=0.04), 
compared to the other TEA clusters. TEA cluster 2, the smallest cluster had the most 
subjects that were hospitalized for asthma (P=0.04). TEA cluster 3, the largest 
cluster, had normal lung function, low exhaled nitric oxide levels, and lower inhaled 
steroid requirements. Evaluation of TEA clusters in children from Asthma BRIDGE 
cohort confirmed that TEA clusters 1 and 2 are associated with a history of 
intubation (P=5.58x10-06) and hospitalization (P=0.01), respectively. Evaluation of 
the TH2 gene signatures suggested a much lower prevalence of TH2 high disease 
than previously reported.
Non-invasive Analysis of the Sputum Transcriptome Discriminates Clinical Phenotypes of Asthma
1Center for Pulmonary Personalized Medicine (P2MED), Section of Pulmonary, Critical Care & Sleep Medicine, Yale School of Medicine - New Haven, CT/US, 2Brigham and Women’s Hospital, and Harvard Medical School -
Boston, MA/US, 3University of Arizona - Tucson, AZ/US, 4University of Chicago - Chicago, IL/US, 5Johns Hopkins University 
- Baltimore, MD/US, 6National Institutes of Health - Research Triangle Park, NC/US, 7Keck School of Medicine, University of Southern California – Los Angeles, CA/US.
Xiting Yan1, Jen-Hwa Chu2, Jose Gomez1, Maria Koenigs1, Carole Holm1, Xiaoxuan He1, Mario F. Perez1, Hongyu Zhao1, Shrikant Mane1, Fernando D. Martinez3, Carole Ober4, Dan L. Nicolae4, Kathleen C. Barnes5, 
Stephanie J. London6, Frank Gilliland7, Scott T. Weiss2, Benjamin A. Raby2, Lauren Cohn1 and Geoffrey L. Chupp1
Background
Abstract
Whole transcriptome wide gene expression profiles in the sputum and circulation 
were measured using the Affymetrix HuGene 1.0ST arrays. Unsupervised 
clustering analysis based on pathways from KEGG were used to identify TEA 
clusters from the sputum gene expression profiles. The identified TEA clusters 
were correlated with clinical, physiologic, and inflammatory characteristics of the 
disease. Lastly, L1 penalized logistic regression analysis of expression profiles in 
matched blood samples defined an expression profile in the circulation which was 
used to determine the TEA cluster assignment in a cohort of children with asthma 
for validation.
Methods
Results
Figure 1. Identification of TEA clusters.
Figure 2. Data visualization of the TEA clusters using the 53 blood expression 
Cluster 1 (N=34) Cluster 2 (N=19) Cluster 3 (N=47) P Value
Prevalence (N) 34 19 47 0.003
Age at Visit (years) 51 ± 13 49 ±16 45 ± 17. 0.32
Female sex, N (%) 23 (68) 15 (79) 39 (83) 0.26
Race 0.58
White - N (%) 22 (65) 14 (74) 37 (79)
Black - N (%) 10 (29) 4 (21) 7 (15)
Other - N (%) 1 (3) 1 (5) 3 (6)
Hispanic Origin - N (%) 1 (3) 4 (21) 7 (15) 0.04
BMI (Kg/m2) 30.0 ± 7.2 30  ± 7.3 29.3 ± 8.0 0.84
History of Atopy - N (%) 33 (97) 14 (74) 43 (92) 0.02
Age of Symptom Onset 25.8 ± 19.1 29.3 ± 20.4 20.7 ± 20.9 0.17
Disease Duration (years) 25.2 ± 17.5 20.7 ± 16.9 24.2 ± 17.3 0.7
History of Hospitalization - N (%) 13 (38.1) 13 (68.4) 16 (34.0) 0.03
History of Intubations - N (%) 6.0 (18) 2.0 (11) 2.0 (4) 0.05
OCS tapers in past year- N (%) 19 (55.9) 12 (63.2) 24 (51.1) 0.67
ACT Score 16 ± 6.4 14 ± 6.6 18 ± 5.1 0.22
ICS dose per day (µg) 617 ± 448 530 ± 449 396 ± 356 0.04
ICS use yes or no – N (%) 27 (79) 17 (89) 31 (66) 0.1
Chronic OCS use (%) 4 (11.8) 2 (10.5) 3 (6.4) 0.68
Cluster 1 (N=34) Cluster 2 (N=19) Cluster 3 (N=47) P Value
FEV1- % of predicted value
Pre β2 agonist use 73 ± 24 76 ± 22 86 ± 22 0.006
Post β2 agonist use 80 ± 24 81 ± 20 91 ± 22 0.493
FVC- % of predicted value
Pre β2 agonist use 85 ± 22 86 ± 18 96 ± 19 0.09
Post β2 agonist use 90±20 88 ± 18 97 ± 18 0.28
FEV1/FVC- % of predicted value
Pre β2 agonist use 0.67 ± 0.13 0.70 ± 0.11 0.72 ± 0.10 0.13
Post β2 agonist use 0.70 ± 0.13 0.72 ± 0.12 0.80 ± 0.10 0.06
BDR (%) 12 ±12 9 ± 13 6 ± 7 0.03
FENO (ppb) 53 ± 43 52 ± 42 38 ± 27 0.04
Cluster 1 (N=34) Cluster 2 (N=19) Cluster 3 (N=47) P Value
Mucus Cell Concentration 83.02±105.75Ρ 89.23±143.61Ρ 73.72±62.48Ρ 0.63
Squamous (%) 7.9±7.0 8.0±5.9 9.2±6.9 0.6
Viability (%) 56.5±16.1 64.4±11.9 61.7±17.8 0.14
Neutrophils (%) 41.5±13.0 41.9±15.2 37.8±14.6 0.34
Eosinophil (%) 5.8±6.7 4.7±5.9 5.2±7.7 0.91
Macrophage (%) 50.9±13.0 50.9±16.0 55.4±15.4 0.31
Lymphocyte (%) 1.3±1.5 1.2±1.0 1.3±1.4 0.9
Bronchial epithelial cell (%) 0.8±1.5 1.3±3.3 0.4±1.0 0.26
RIN (mean) 7.4±1.2 7.5±1.0 7.7±1.4 0.1
Table 1. Demographical, pulmonary function and sputum characteristics of the TEA clusters in YCAAD cohort.
Cluster 1 (N=266) Cluster 2 (N=105) Cluster 3 (N=499) P Value
Age at Visit (years) 14.8 ± 8 10.1 ± 5 12.6 ± 7 3.27 x 10-08
Sex, N (%) Female 128 (48) 45 (43) 212 (43) 0.31
Race 1.68 x 10-07
White - N (%) 102 (38) 79 (75) 284 (57)
Black - N (%) 105 (40) 9 (9) 124 (25)
Other - N (%) 29 (11) 7 (7) 37 (7)
Hispanic Origin - N (%) 30 (11) 10 (10) 54 (11) 0.09
History of Atopy - N (%) 69 (26) 40 (38) 113 (23) 0.0013
Age of Symptom Onset 3.50 ± 3.21 3.32 ± 2.89 3.48 ± 2.80 0.86
History of Hospitalization - N (%) 91 (34) 37 (35) 128 (26) 0.011
History of Intubations - N (%) 21 (8) 0 (0) 9 (2) 5.58 x 10-06
ACT Score 14 ± 4 12 ± 3 13 ± 3 8.79 x 10-07
Table 2. Phenotypes of the TEA clusters in the validation cohort.
Conclusions
Gene Name Gene Symbol Biological Processes Function
Fold 
Chan
ge
Pvalu
e FDR
Pubm
ed
Hemogen HEMGN apoptosis Transcription Factor 1.25
2.79x
10-7
4.01x
10-3 16
piccolo (presynaptic cytomatrix protein) PCLO cytoskeleton organization Protein 1.21 6.26x10-7
4.01x
10-3 26regulation of exocytosis
cartilage associated protein CRTAP extracellular matrix organization
Scaffolding 
Protein -1.48
7.87x
10-7
4.01x
10-3 25
exosome component 9 EXOSC9 RNA processing
RNase 
Complex 
Component
-2.1 1.11x10-6
4.01x
10-3 32
chromosome 9 open reading frame 173 C9orf173 N/A N/A 1.36
1.23x
10-6
4.01x
10-3 2
small nuclear RNA activating complex, 
polypeptide 5, 19kDa
SNAPC
5
DNA-dependent regulation 
of transcription
Transcriptio
n Factor -1.08
1.23x
10-6
4.01x
10-3 9
impact RWD domain protein IMPACT negative regulation of protein phosphorylation Enzyme -2.12
1.44x
10-6
4.01x
10-3 11
solute carrier family 4, sodium bicarbonate 
cotransporter, member 4 SLC4A4 sodium ion transport
Membrane 
Transporter 
Protein
1.22 1.45x10-6
4.01x
10-3 61
histidine decarboxylase HDC histamine biosynthesis Enzyme 1.39 1.94x10-6
4.78x
10-3 48
neuronal cell adhesion molecule NRCAM neuron migration
Cell 
Adhesion 
Molecules
1.19 2.29x10-6
5.08x
10-3 40
Gene Name Gene Symbol
Biological 
Processes Functions
Fold 
Chan
ge
Pvalu
e FDR
Pub
med
heart development protein with EGF-like 
domains 1 HEG1
endothelial cell 
angilgenesis
Cell adhesion 
molecules 1.78
1.09x
10-7
2.42x
10-3 7
small nucleolar RNA, C/D box 104 SNORD104
RNA 
modification non-coding RNA 2.58
2.46x
10-7
2.73x
10-3 2
dynein, axonemal, heavy chain 17 DNAH17 ciliary motility
microtubule-
associated motor 
protein
1.88 2.61x10-6
1.18x
10-2 7
Cbl proto-oncogene, E3 ubiquitin protein ligase 
B CBLB
regulation of T 
cell anergy
ubiquitin protein 
ligase 2.04
2.95x
10-6
1.18x
10-2 93
defensin, beta 1 DEFB1 Innate Immune Response antimicrobial peptide 2.85
2.97x
10-6
1.18x
10-2 133
non-protein coding RNA 204 NCRNA204 N/A non-coding RNA 2.2
3.55x
10-6
1.18x
10-2 1
transcription elongation factor A (SII) N-
terminal and central domain containing
TCEAN
C RNA elongation
transcription 
elongation factor 2.22
6.58x
10-6
1.82x
10-2 10
radical S-adenosyl methionine domain 
containing 2 RSAD2
regulation of toll-
like 
antiviral protein 1.57 1.04x10-5
2.07x
10-2 28receptor 9 
signaling 
pathway
purinergic receptor P2Y, G-protein coupled, 14 P2RY14 regulation of inflammation UDP-glucose receptor 5.14
1.04x
10-5
2.07x
10-2 31
malignant fibrous histiocytoma amplified 
sequence
MFHAS
1 cell cycle Protein 4.14
1.11x
10-5
2.07x
10-2 11
Table 3. Top 10 differentially expressed genes between TEA 1 versus controls and TEA 3 versus 
controls. 
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